OBESITY-ASSOCIATED BONE METABOLIC DYSFUNCTION IN POSTMENOPAUSAL WOMEN: A SYSTEMATIC EVIDENCE REVIEW OF ADIPOKINE SIGNALING, INFLAMMATORY MECHANISMS, AND SKELETAL OUTCOMES (2020–2026)
Keywords:
postmenopause; obesity; visceral adipose tissue; bone mineral density; trabecular bone score; adipokines; inflammation; fracture; sarcopenic obesity.Abstract
Background: Obesity is common after menopause, yet its relationship with skeletal health is complex. Greater body mass may increase areal bone mineral density (BMD), while visceral adiposity, inflammation, altered adipokine signaling, and loss of muscle function may adversely affect bone quality and fracture risk.
Objective: To summarize evidence published from 2020 to 2026 on the associations between obesity, adipose-tissue signaling, bone metabolism, bone microarchitecture, and fracture outcomes in postmenopausal women.
Methods: A focused evidence search was undertaken for studies and reviews addressing postmenopausal women, obesity or adiposity, bone health, bone turnover, trabecular bone score (TBS), and fractures. Relevant observational studies, cohort studies, meta-analyses, and mechanistic reviews were narratively synthesized. This document is a PRISMA-informed evidence-review draft; it does not claim completion of a fully reproducible multi-database systematic search, duplicate removal, dual independent screening, or formal risk-of-bias assessment.
Results: Evidence indicates that the relationship between obesity and skeletal outcomes is site- and phenotype-dependent. A meta-analysis of eight cohorts including 671,532 postmenopausal women reported an increased overall fracture risk (RR 1.18, 95% CI 1.09–1.28), with different associations across fracture sites. Studies also associate visceral adiposity with less favorable bone turnover markers and lower TBS. In women with morbid obesity, BMD alone may not fully reflect impaired bone microarchitecture. Sarcopenic obesity appears particularly relevant to falls and fragility fractures.
Conclusion: Obesity should not be considered uniformly protective against postmenopausal osteoporosis. Assessment of central adiposity, muscle status, bone quality, and fracture history may complement BMD. Prospective studies with standardized adiposity and skeletal measures are needed.
References
1. Sharma DK, et al. Visceral Fat Is a Negative Determinant of Bone Health in Obese Postmenopausal Women. Int J Environ Res Public Health. 2020;17(11):3996. doi:10.3390/ijerph17113996.
2. Jose A, et al. Trabecular Bone Score and Bone Mineral Density in Postmenopausal Women with Morbid Obesity—A Clinical Paradox. Medicina (Kaunas). 2021;9(4):69. [Verify journal title and bibliographic metadata against the publisher record before submission].
3. Gandham A, et al. Falls, fractures, and areal bone mineral density in older adults with sarcopenic obesity: a systematic review and meta-analysis. Obes Rev. 2021;22(5):e13187. doi:10.1111/obr.13187.
4. Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71.
5. Lin YH, Teng MMH. Association of possible sarcopenic obesity with osteoporosis and fragility fractures in postmenopausal women. Arch Osteoporos. 2022;17:65. doi:10.1007/s11657-022-01107-8.
6. Liu HF, Meng DF, Yu P, De JC, Li HY. Obesity and risk of fracture in postmenopausal women: a meta-analysis of cohort studies. Ann Med. 2023;55(1):2203515. doi:10.1080/07853890.2023.2203515.
7. Lee J, et al. Associations between body composition and the risk of fracture according to bone mineral density in postmenopausal women: a population-based database cohort study. Eur J Endocrinol. 2023;189(5):527-536. doi:10.1093/ejendo/lvad156.
8. Niu H, et al. Bone Marrow Adipose Tissue as a Critical Regulator of Postmenopausal Osteoporosis - A Concise Review. Clin Interv Aging. 2024;19:1259-1272. doi:10.2147/CIA.S466446.
9. Chondrogianni ME, et al. Body composition as an index of the trabecular bone score in postmenopausal women. Maturitas. 2025;198:108273. doi:10.1016/j.maturitas.2025.108273.
10. Beaudart C, et al. GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis. Drugs. 2026;86(10):1661-1691. doi:10.1007/s40265-026-02365-3.
11. Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393(10169):364-376. doi:10.1016/S0140-6736(18)32112-3.
12. Cawthon PM, et al. Sarcopenia and physical performance in older adults: a review of definitions and clinical implications. [Add verified full bibliographic details before submission].
13. Reid IR. Relationships between fat and bone. Osteoporos Int. 2010;21:179-185. doi:10.1007/s00198-009-1035-0.
14. Rosen CJ, Bouxsein ML. Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol. 2006;2:35-43. doi:10.1038/ncprheum0070.
15. Kawai M, Devlin MJ, Rosen CJ. Fat targets for skeletal health. Nat Rev Rheumatol. 2009;5:365-372. doi:10.1038/nrrheum.2009.113.
